

Oregon Prescription Drug Monitoring Program Advisory Commission

January 11, 2013 Meeting Minutes

1:00 PM to 4:00 PM

Portland State Office Building

800 NE Oregon Street, **Room 918**

Portland, OR 97232

ATTENDEES

Advisory Commission Present: Michael Millard, Chris Apgar, Therese Hutchinson, Lindsay Jenkins, Teresa Keane, Sara Love, Al Turner, Mark Williams

Advisory Commission Absent: Larissa Jeffreys, Bill Jordan, Theresa Muday

OHA Staff: Lisa Millet, Todd Beran, Samantha Greene, Mary Yang

Guests: Becky Strauss

Decisions

1. The meeting minutes from October 2012 were approved as drafted
2. The meeting schedule was changed for 2013. The upcoming schedule is: April 26, July 19, and October 18.

INTRODUCTIONS

The meeting was called to order by Millard at 1:10 p.m. Attendees introduced themselves.

OLD BUSINESS

a. Review of 10/12/2011 meeting minutes

The meeting minutes were reviewed and approved as written.

NEW BUSINESS

a. Review monthly and YTD metrics

Beran and Millet gave an overview of the monthly and to-date reports.

Keane asked about morphine equivalency. Beran explained that the number of days is not collected in the system so it is not possible at this time to calculate morphine equivalent dosage.

b. Review the ORPDMP Annual Report

Minutes approved 4/26/13

Millet gave an introduction and summary of the State PDMP Annual report. The Advisory Commission expressed their approval of the report.

OPEN ISSUES

- Apgar and Love cautioned against integrating the PDMP with Epic.
- The Advisory Commission requested an update on the PDMP legislative concept. Millet responded that the LC was not moving forward through the Oregon Health Authority.
- Turner noted an issue with Safeway pharmacy data not showing up in the system.
- The Advisory Commission noted that the format in which the system generates the report is hard to read and inquired about possible changes.
- Millet discussed the Governor's task force on prescription drug abuse. She noted a strong commitment to improving patient care, developing practice guidelines, and ensuring access to treatment and pain management resources.
- Keane requested more information on the federal DEA subpoena as is allowed.

PUBLIC COMMENT

Becky Strauss of the Oregon ACLU stated that she and her organization will continue to watch the ongoing litigation between the federal DEA and Oregon. The ACLU's concern is misuse of the PDMP system by law enforcement and inappropriate surveillance of patients to deny medications. She stressed the importance of maintaining individuals' privacy and not expanding access to system information.